GlassScriptPhysician profile
Allan D Mineroff
NPI 1134159858
$5,336.22
in general payments reported to CMS, 2019-2025
24 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $144 · 2021: $199 · 2022: $472 · 2023: $1,421 · 2024: $1,115 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.54 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,676.64 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $661.81 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $414.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $381.27 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $355.62 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $339.08 | 2023-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $303.72 | 2019 | |
| Leo Pharma INC. | $193.44 | 2019-2024 | Adbry |
| Lilly USA, LLC | $185.83 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Celgene Corporation | $127.37 | 2019 | |
| Genzyme Corporation | $107.83 | 2023-2025 | |
| Amgen INC. | $67.92 | 2023-2024 | Otezla |
| Ucb, INC. | $66.75 | 2019-2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $62.23 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $60.17 | 2020-2024 | Aklief |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $56.66 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $56.55 | 2019 | |
| Incyte Corporation | $49.92 | 2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $46.17 | 2023-2025 | Ycanth |
| Pfizer INC. | $33.45 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $29.54 | 2023 | Valchlor |
| Epi Health, LLC | $21.55 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.86 | 2019 | |
| Almirall LLC | $18.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Mineroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.